A Global Innovator in
Regenerative Medicine
Tetratherix is an Australian medtech pioneer that has developed an advanced biomaterial platform called Tetramatrix.
Mission
Our mission is to extend and improve the lives of 10 million people around the world over the next 10 years with Tetramatrix utilised in multiple forms for a range of clinical applications. We measure our success by how many lives we change and believe our social obligation is to ensure access to Tetramatrix is easy and affordable for every community around the world.
1 / 3
0 People
Global Reach
0 Years
Regenerative Platform
The Tetramatrix
Pillars of Innovation

Tetramatrix is a flowable biomaterial that forms an adhesive and biomimetic scaffold when administered to the body. Tetramatrix hydrogel provides an optimal environment for cell infiltration and blood vessel ingrowth to complement the innate healing process across different tissues and therefore provides a true regenerative platform. The core technology of the platform is a smart polymer that consists of 4 key building blocks to deliver 4 key properties which in combination makes the technology unique.

1 / 2
Synthetic & Scalable Production
A single formulation of the product addresses different unmet clinical needs. Tetramatrix is fully synthetic and does not rely on human- or animal-derived material, ensuring cost-effective and scaled manufacturing in large quantities.
Unique Physical Properties
The product is a water-based solution that transitions into an adhesive and elastic hydrogel to allow minimally invasive administration. The gelation process is purely physical and triggered by physiological temperature to preserve the natural healing capability of the body.
Highly Biocompatible
Tetramatrix is biocompatible and has been demonstrated to be well tolerated in numerous preclinical and clinical studies, performed over a decade of research. Nearly 20 patients have been treated with the technology with no adverse events.
Regenerative Platform
Tetramatrix supports and enhances the natural healing capability of the host tissue by providing a cell-permeable scaffold to allow progenitor cells to grow within its structure. Over time, the product resorbs and is replaced with healthy tissue.
Anchored by Science
In the early days of his research, Dr Ali Fathi recognised the human body’s ability to function as the optimal bioreactor for tissue regeneration. Ali’s PhD at the University of Sydney, focused on the development of a smart biomaterial using the innate ability of the body to repair damaged tissue. Anchored by science, this was the genesis of Tetramatrix and the subsequent family of patents and publications that would follow. Ali was inspired by his entrepreneurial awareness of the impact that this translational science would have on patients around the world.
Focused and Agile
As a fellow chemical engineer at the University of Sydney, Terence Abrams was introduced to the technology and shared Ali’s enthusiasm for Tetramatrix. Armed with the experience and understanding of bespoke chemical manufacturing, Tez worked with Ali to incorporate the company Tetratherix and secure seed funding and crucial government grants. By 2017 they had established their own certified production facility in Sydney, followed shortly by the first clinical trial of the technology and successful IP assignment in 2019.
Geared for Growth
While leading the development and commercialization of innovations in regenerative medicine, Will Knox was introduced to Tetratherix in 2018. Will’s experience in managing global commercialization of medtech shaped a unique appreciation for the technology’s wide-reaching clinical benefit and exciting market potential. The founding team was completed by Will’s appointment as CEO which provides the commercial context to define and deliver the Tetratherix mission, vision and culture. Leading innovation in regenerative medicine and with a clear path to global expansion, we are geared for growth and excited about our future.
1 / 3
People
Experience, Energy,
Reputation, Execution.
Dr Simin Maleknia
Senior Production Manager
Ruth Cremin
Quality & Regulatory Manager
Will Knox
CEO
Dr Jo Maitz
Clinical Affairs Director
Dr Ali Fathi
Founder & CTO
Kim Steel
Clinical Trial Manager
Terence Abrams
Founder & COO
Jeff Reid
Corporate Development Manager

As a world-class researcher with decades of experience in translational research, Simin manages and drives our production program. Combining both a calm temperament and a meticulous nature, Simin is our production and research North Star.

LinkedIn

Ruth has unparalleled experience in the quality and regulatory functions of the global medical device industry, which are critical in her role to obtain registration and market clearance for Tetramatrix. Ruth has a unique ability to be both dynamic and meticulous in how she applies her skill set – a rarity in the industry.

LinkedIn

Will provides the commercial context to define and deliver the Tetratherix mission, vision and culture. Will’s prior success in commercialisation and development of life-changing MedTech innovations are paramount to the company’s global ambitions.

LinkedIn

As a clinician and a driven researcher, Jo’s unique skill set facilitates effective engagement and collaboration with key opinion leaders to define the clinical utility of Tetramatrix. Jo is hardworking, diligent and precise, making her an integral part of the team.

LinkedIn

Ali is a world-renowned researcher and inventor of Tetramatrix and has continued the development of the technology using his technical and entrepreneurial vision. Ali’s scientific approach to problem-solving and his tenacity are central to bringing the technology into the hands of clinicians.

LinkedIn

Kim’s proficient and driven management of our clinical trial program has enabled us to establish an adoptable and efficient cadence in our clinical validation. Her calm and confident decision-making complements her ability to energise those around her.

LinkedIn

As an engineer, Terence is armed with the experience and understanding of bespoke chemical manufacturing. A natural problem solver with the ability to think outside the box, Terence has been instrumental in process design and optimisation to allow production of Tetramatrix at scale.

LinkedIn

Jeff’s decades of experience in successful commercialisation of medical innovations forms a platform that helps to define our commercial development program, including key partnership management and pipeline strategy. Jeff’s extensive knowledge of execution and accountability in the market ensures that our development program meets our commercial objectives.

LinkedIn

Prof Dax Calder
Scientific Advisor | Regenerative Skeletal Reconstruction
Rob McInnes
Transaction Advisor
Prof Ali Khademhosseini
Scientific Advisor | Tissue Engineering
Dr Drew Cronin
Scientific Advisor | Surgical Wound

Dax is a specialist periodontist with a passion to simplify and improve techniques relating to dental implant surgeries and bone augmentation procedures. Dax is a long-time supporter of Tetratherix and was the first surgeon to explore Tetramatrix in a clinical setting. 

LinkedIn

For nearly a decade, Rob has been ranked as Australia’s highest recommended patent and technology licensing lawyer. He specializes in the commercialisation of novel technologies, and in aspects of major corporate transactions related to intellectual property. 

LinkedIn

Ali is the CEO of the Terasaki Institute and former Professor at the University of California, Los Angeles, Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering. Ali has been selected by Thomson Reuters as one of the World’s Most Influential Minds since 2014.

LinkedIn

Drew is a board-certified plastic and reconstructive surgeon with a passion for complex skin cancer excision and surgical reconstruction. Drew has been the winner of the prestigious Emmett Prize for most outstanding registrar research in Australia and New Zealand. 

Valley Plastic Surgery

Careers
Facility
Tetratherix has established its own production facility in Alexandria, Sydney. The company’s clean room production facility is fully equipped to manufacture sterile medical devices on a commercial scale. The infrastructure and the associated quality management system are ISO 13485:2016 certified.
Production
Tetratherix’s in-house production facility is of great importance for quality control, product development and production scalability. In addition, our production capability facilitates efficient product development and collaborative global partnerships.
1 / 2
Applications
News & Publications
Research & Discover
Smart Nanogel for Intranasal Brain Delivery of RNA
August 5, 2022

Tetratherix is pleased to announce the support of NSW Healths ‘RNA Future Leaders Program’ to expand the application of our platform technology for nasal delivery of RNA for the treatment of Alzheimer’s Disease.

Read More
Engineers Australia – Repair Work
June 20, 2022

create digital recently featured our founders in their publication for Engineers Australia to highlight the novel biochemistry in our biopolymer platform. Ali Fathi and Terence Abrams have worked hard for many years, dedicated to delivering medical innovation with real world application – something that has shaped the core of…

Read More